Table A4:

Results of Deterministic Sensitivity Analyses

Variable	Estimate (Upper or Lower Bound)	ICER LAAC Device:Apixaban ($/QALY)	ICER LAAC Device:Dabigatran ($/QALY)	ICER LAAC Device:Rivaroxaban ($/QALY)	ICER LAAC Device:Warfarin ($/QALY)
Clinical Event Rates and Treatment Costs
Device embolization	Upper	Dominated	Dominated	Dominated	210,109
	Lower	Dominated	Dominated	Dominated	208,268
Pericardial effusion	Upper	Dominated	Dominated	Dominated	162,904
	Lower	Dominated	Dominated	Dominated	157,877
LAAC device implantation	Upper	Dominated	Dominated	Dominated	176,767
unsuccessful	Lower	Dominated	Dominated	Dominated	211,777
Baseline thromboembolic event rate (by CHA2DS2VASc score)	Upper	Dominated	Dominated	Dominated	218,622
	Lower	426,041	812,338	36,468	45,423
Baseline hemorrhagic stroke rate (by HAS-BLED score)	Upper	Dominated	Dominated	Dominated	240,387
	Lower	Dominated	Dominated	Dominated	Dominated
Baseline major bleed rate (by HAS-BLED score)	Upper	Dominated	Dominated	Dominated	234,201
	Lower	Dominated	Dominated	Dominated	209,948
OR of ischemic stroke, LAAC device: warfarin	Upper	Dominated	Dominated	Dominated	Dominated
	Lower	71,228	82,185	14,331	28,414
OR of hemorrhagic stroke, LAAC device: warfarin	Upper	Dominated	Dominated	Dominated	729,937
	Lower	Dominated	Dominated	Dominated	145,689
OR of major bleed, LAAC device: warfarin	Upper	Dominated	Dominated	Dominated	Dominated
	Lower	Dominated	Dominated	Dominated	143,707
Clinical Event Rates and Treatment Costs
Probability of fatal, major, moderate, and minor ischemic and hemorrhagic stroke	–	Dominated	Dominated	Dominated	290,357
Utilities
Myocardial infarction, first year	Upper	Dominated	Dominated	Dominated	236,296
	Lower	Dominated	Dominated	Dominated	234,130
Myocardial infarction, second year	Upper	Dominated	Dominated	Dominated	158,183
	Lower	Dominated	Dominated	Dominated	158,183
Myocardial infarction, third year	Upper	Dominated	Dominated	Dominated	163,487
	Lower	Dominated	Dominated	Dominated	163,487
Stroke
Major (1 month)	Upper	Dominated	Dominated	Dominated	218,413
	Lower	Dominated	Dominated	Dominated	218,718
Major (post–1 month)	Upper	Dominated	Dominated	Dominated	204,385
	Lower	Dominated	Dominated	Dominated	190,735
Moderate (1 month)	Upper	Dominated	Dominated	Dominated	151,644
	Lower	Dominated	Dominated	Dominated	318,747
Moderate (post–1 month)	Upper	Dominated	Dominated	Dominated	184,047
	Lower	Dominated	Dominated	Dominated	296,280
Minor (1 month)	Upper	Dominated	Dominated	Dominated	246,114
	Lower	Dominated	Dominated	Dominated	314,504
Minor (post–1 month)	Upper	Dominated	Dominated	Dominated	218,931
	Lower	Dominated	Dominated	Dominated	212,898
Costs
Cost of device	Upper	Dominated	Dominated	Dominated	270,663
	Lower	Dominated	Dominated	Dominated	154,148
Physician fees	Upper	Dominated	Dominated	Dominated	167,800
	Lower	Dominated	Dominated	Dominated	155,330

Abbreviations: CHADS₂DS₂VASc, Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, Stroke or transient ischemic attack symptoms previously (2 points), Vascular disease, Age 65–74 years, Sex category; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratios (INRs), Elderly, Drugs or alcohol; ICER, incremental cost-effectiveness ratio; LAAC device, left atrial appendage closure device with delivery system; OR, odds ratio; QALY, quality-adjusted life-year.